NASDAQ:LSTA Lisata Therapeutics (LSTA) Stock Price, News & Analysis $3.40 -0.03 (-0.87%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.36▼$3.4050-Day Range$2.82▼$3.7052-Week Range$1.95▼$3.83Volume3,817 shsAverage Volume14,820 shsMarket Capitalization$28.25 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Lisata Therapeutics alerts: Email Address Lisata Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside341.2% Upside$15.00 Price TargetShort InterestHealthy0.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.08) to ($2.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.22 out of 5 starsMedical Sector361st out of 936 stocksPharmaceutical Preparations Industry168th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingLisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLisata Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Lisata Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.16% of the float of Lisata Therapeutics has been sold short.Short Interest Ratio / Days to CoverLisata Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lisata Therapeutics has recently decreased by 22.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLisata Therapeutics does not currently pay a dividend.Dividend GrowthLisata Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LSTA. Previous Next 1.7 News and Social Media Coverage News SentimentLisata Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Lisata Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for LSTA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of Lisata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.94% of the stock of Lisata Therapeutics is held by institutions.Read more about Lisata Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lisata Therapeutics are expected to grow in the coming year, from ($3.08) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lisata Therapeutics is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lisata Therapeutics is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLisata Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lisata Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Lisata Therapeutics Stock (NASDAQ:LSTA)Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Read More LSTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LSTA Stock News HeadlinesJuly 22, 2024 | benzinga.comLisata Therapeutics (NASDAQ:LSTA) Stock Quotes, Forecast and News SummaryJuly 20, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Lisata Therapeutics (NASDAQ:LSTA)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 19, 2024 | markets.businessinsider.comHaystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer TherapyJuly 19, 2024 | finance.yahoo.comHaystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer TherapyJuly 19, 2024 | msn.comEXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy EfficacyJuly 18, 2024 | proactiveinvestors.comLisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy researchJuly 18, 2024 | globenewswire.comHaystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer TherapyJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 16, 2024 | proactiveinvestors.comLisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancerJuly 16, 2024 | globenewswire.comLisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line CholangiocarcinomaJuly 13, 2024 | proactiveinvestors.comLisata's certepetide showing promising early results as cholangiocarcinoma treatment – ICYMIJuly 10, 2024 | proactiveinvestors.comLisata Therapeutics shares promising pre-clinical dataJuly 10, 2024 | globenewswire.comLisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical ModelJune 18, 2024 | proactiveinvestors.comLisata Therapeutics CEO discusses enrollment milestone for pancreatic cancer trialJune 13, 2024 | proactiveinvestors.comLisata Therapeutics completes pancreatic cancer cohort enrollment in CENDIFOX trialJune 13, 2024 | globenewswire.comLisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX TrialMay 29, 2024 | proactiveinvestors.comHow does Lisata Therapeutics have a negative enterprise value?See More Headlines Receive LSTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LSTA CUSIPN/A CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+345.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.90% Return on Assets-35.91% Debt Debt-to-Equity RatioN/A Current Ratio8.92 Quick Ratio8.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.88 per share Price / Book0.57Miscellaneous Outstanding Shares8,310,000Free Float6,513,000Market Cap$28.00 million OptionableNot Optionable Beta1.24 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. David J. Mazzo B.A. (Hons) (Age 67)B.Sc. (Hons.), M.Sc., Ph.D., President, CEO & Director Comp: $1.16MDr. Kristen K. Buck M.D. (Age 50)Executive VP of R&D and Chief Medical Officer Comp: $938.42kMr. James Nisco (Age 53)Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Mr. Tariq ImamVice President of Business Development & Operations and Corporate CounselMr. Gregory S. BerkinChief Information OfficerMr. John D. MendittoVice President of Investor Relations & Corporate CommunicationsMs. Gail Holler (Age 65)Vice President of Human Resources Dr. William K. Sietsema Ph.D. (Age 68)Vice President of Global Regulatory Affairs Comp: $350.55kMore ExecutivesKey CompetitorsKentucky First Federal BancorpNASDAQ:KFFBOrgenesisNASDAQ:ORGSOntrakNASDAQ:OTRKLumos PharmaNASDAQ:LUMONeos TherapeuticsNASDAQ:NEOSView All Competitors LSTA Stock Analysis - Frequently Asked Questions How have LSTA shares performed this year? Lisata Therapeutics' stock was trading at $2.73 on January 1st, 2024. Since then, LSTA stock has increased by 24.5% and is now trading at $3.40. View the best growth stocks for 2024 here. How were Lisata Therapeutics' earnings last quarter? Lisata Therapeutics, Inc. (NASDAQ:LSTA) posted its earnings results on Thursday, May, 9th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. How do I buy shares of Lisata Therapeutics? Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LSTA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.